AVALO THERAPEUTICS, INC. Operating Cash Flow
AVALO THERAPEUTICS, INC. (AVTX) reported Operating Cash Flow of -$37.68 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06
- AVALO THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$19.99M.
- AVALO THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$17.69M.
- AVALO THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$14.25M.
- AVALO THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$16.36M.
- AVALO THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$51.46M.
- AVALO THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$49.06M.
- AVALO THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$30.68M.
- AVALO THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$26.75M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$19.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$37.68M 10-Q · filed 2026-08-06 | -$51.92M derived: sum of 3 quarters · filed 2026-08-06 | -$68.29M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | -$17.69M 10-Q · filed 2026-05-13 | -$31.94M derived: sum of 2 quarters · filed 2026-05-13 | -$48.30M derived: sum of 3 quarters · filed 2026-05-13 | -$59.69M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | -$14.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$30.61M derived: sum of 2 quarters · filed 2026-03-23 | -$42.00M derived: sum of 3 quarters · filed 2026-08-06 | -$51.46M 10-K · filed 2026-03-23 | ||||
| 2025-09-30 | -$16.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$27.75M derived: sum of 2 quarters · filed 2026-08-06 | -$37.21M 10-Q · filed 2025-11-06 | -$52.26M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | -$11.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$20.85M 10-Q · filed 2026-08-06 | -$35.89M derived: sum of 3 quarters · filed 2026-08-06 | -$47.42M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | -$9.46M 10-Q · filed 2026-05-13 | -$24.50M derived: sum of 2 quarters · filed 2026-05-13 | -$36.03M derived: sum of 3 quarters · filed 2026-05-13 | -$52.31M derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2024-12-31 | -$15.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$26.57M derived: sum of 2 quarters · filed 2026-03-23 | -$42.85M derived: sum of 3 quarters · filed 2026-03-23 | -$49.06M 10-K · filed 2026-03-23 | ||||
| 2024-09-30 | -$11.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$27.81M derived: sum of 2 quarters · filed 2025-11-06 | -$34.01M 10-Q · filed 2025-11-06 | -$36.78M derived: sum of 4 quarters · filed 2025-11-06 | ||||
| 2024-06-30 | -$16.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$22.48M 10-Q · filed 2025-08-07 | -$25.25M derived: sum of 3 quarters · filed 2025-08-07 | -$32.09M derived: sum of 4 quarters · filed 2025-08-07 | ||||
| 2024-03-31 | -$6.20M 10-Q · filed 2025-05-12 | -$8.97M derived: sum of 2 quarters · filed 2025-05-12 | -$15.80M derived: sum of 3 quarters · filed 2025-05-12 | -$26.83M derived: sum of 4 quarters · filed 2025-05-12 | ||||
| 2023-12-31 | -$2.77M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$9.60M derived: sum of 2 quarters · filed 2025-03-20 | -$20.63M derived: sum of 3 quarters · filed 2025-03-20 | -$30.68M 10-K · filed 2025-03-20 | ||||
| 2023-09-30 | -$6.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$17.86M derived: sum of 2 quarters · filed 2024-11-07 | -$27.91M 10-Q · filed 2024-11-07 | -$31.85M derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2023-06-30 | -$11.03M derived: 10-Q 6 month − 10-Q/A 3 month · filed 2024-08-12 | -$21.08M 10-Q · filed 2024-08-12 | -$25.02M derived: sum of 3 quarters · filed 2024-08-12 | -$19.29M derived: sum of 4 quarters · filed 2024-08-12 | ||||
| 2023-03-31 | -$10.05M 10-Q/A · filed 2024-07-11 | -$13.99M derived: sum of 2 quarters · filed 2024-07-11 | -$8.27M derived: sum of 3 quarters · filed 2024-07-11 | -$20.74M derived: sum of 4 quarters · filed 2024-07-11 | ||||
| 2022-12-31 | -$3.94M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $1.79M derived: sum of 2 quarters · filed 2024-03-29 | -$10.68M derived: sum of 3 quarters · filed 2024-03-29 | -$26.75M 10-K · filed 2024-03-29 | ||||
| 2022-09-30 | $5.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$6.74M derived: sum of 2 quarters · filed 2023-11-09 | -$22.81M 10-Q · filed 2023-11-09 | -$39.91M derived: sum of 4 quarters · filed 2023-11-09 | ||||
| 2022-06-30 | -$12.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$28.54M 10-Q · filed 2023-08-03 | -$45.64M derived: sum of 3 quarters · filed 2023-08-03 | -$61.93M derived: sum of 4 quarters · filed 2023-08-03 | ||||
| 2022-03-31 | -$16.07M 10-Q · filed 2023-05-04 | -$33.17M derived: sum of 2 quarters · filed 2023-05-04 | -$49.46M derived: sum of 3 quarters · filed 2023-05-04 | -$68.64M derived: sum of 4 quarters · filed 2023-05-04 | ||||
| 2021-12-31 | -$17.10M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | -$33.39M derived: sum of 2 quarters · filed 2023-03-29 | -$52.58M derived: sum of 3 quarters · filed 2023-03-29 | -$70.89M 10-K · filed 2023-03-29 | ||||
| 2021-09-30 | -$16.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | -$35.48M derived: sum of 2 quarters · filed 2022-11-07 | -$53.79M 10-Q · filed 2022-11-07 | -$68.17M derived: sum of 4 quarters · filed 2022-11-07 | ||||
| 2021-06-30 | -$19.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$37.50M 10-Q · filed 2022-08-04 | -$51.88M derived: sum of 3 quarters · filed 2022-08-04 | -$63.75M derived: sum of 4 quarters · filed 2022-08-04 | ||||
| 2021-03-31 | -$18.32M 10-Q · filed 2022-05-05 | -$32.69M derived: sum of 2 quarters · filed 2022-05-05 | -$44.56M derived: sum of 3 quarters · filed 2022-05-05 | -$53.12M derived: sum of 4 quarters · filed 2022-05-05 | ||||
| 2020-12-31 | -$14.38M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-02 | -$26.25M derived: sum of 2 quarters · filed 2022-03-02 | -$34.80M derived: sum of 3 quarters · filed 2022-03-02 | -$40.54M 10-K · filed 2022-03-02 | -$40.54M 10-K · filed 2021-03-08 | |||
| 2020-09-30 | -$11.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$20.43M derived: sum of 2 quarters · filed 2021-11-09 | -$26.16M 10-Q · filed 2021-11-09 | -$26.16M 10-Q · filed 2020-11-09 | -$27.84M derived: sum of 4 quarters · filed 2021-11-09 | |||
| 2020-06-30 | -$8.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-02 | -$14.29M 10-Q · filed 2021-08-02 | -$14.29M 10-Q · filed 2020-08-06 | -$15.97M derived: sum of 3 quarters · filed 2021-08-02 | -$23.59M derived: sum of 4 quarters · filed 2021-08-02 | |||
| 2020-03-31 | -$5.74M 10-Q · filed 2021-05-13 | -$5.74M 10-Q · filed 2020-05-07 | -$7.42M derived: sum of 2 quarters · filed 2021-05-13 | -$15.03M derived: sum of 3 quarters · filed 2021-05-13 | -$21.75M derived: sum of 4 quarters · filed 2021-05-13 | |||
| 2019-12-31 | -$1.68M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | -$9.30M derived: sum of 2 quarters · filed 2021-03-08 | -$16.01M derived: sum of 3 quarters · filed 2021-03-08 | -$19.13M 10-K · filed 2021-03-08 | ||||
| 2019-09-30 | -$7.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$14.33M derived: sum of 2 quarters · filed 2020-11-09 | -$17.45M 10-Q · filed 2020-11-09 | -$19.43M derived: sum of 4 quarters · filed 2020-11-09 | ||||
| 2019-06-30 | -$6.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$9.84M 10-Q · filed 2020-08-06 | -$11.81M derived: sum of 3 quarters · filed 2020-08-06 | -$12.35M derived: sum of 4 quarters · filed 2020-08-06 | ||||
| 2019-03-31 | -$3.12M 10-Q · filed 2020-05-07 | -$5.10M derived: sum of 2 quarters · filed 2020-05-07 | -$5.64M derived: sum of 3 quarters · filed 2020-05-07 | -$5.97M derived: sum of 4 quarters · filed 2020-05-07 | ||||
| 2018-12-31 | -$1.98M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | -$2.51M derived: sum of 2 quarters · filed 2020-03-11 | -$2.85M derived: sum of 3 quarters · filed 2020-03-11 | -$3.13M 10-K · filed 2020-03-11 | ||||
| 2018-09-30 | -$538.35K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | -$872.02K derived: sum of 2 quarters · filed 2019-11-14 | -$1.15M 10-Q · filed 2019-11-14 | -$3.70M derived: sum of 4 quarters · filed 2019-11-14 | ||||
| 2018-06-30 | -$333.67K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | -$614.10K 10-Q · filed 2019-08-08 | -$3.16M derived: sum of 3 quarters · filed 2019-08-08 | $15.96M derived: sum of 4 quarters · filed 2019-08-08 | ||||
| 2018-03-31 | -$280.42K 10-Q · filed 2019-05-09 | -$2.83M derived: sum of 2 quarters · filed 2019-05-09 | $16.29M derived: sum of 3 quarters · filed 2019-05-09 | $14.53M derived: sum of 4 quarters · filed 2019-05-09 | ||||
| 2017-12-31 | -$2.55M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $16.57M derived: sum of 2 quarters · filed 2019-03-18 | $14.82M derived: sum of 3 quarters · filed 2019-03-18 | $12.58M 10-K · filed 2019-03-18 | $12.52M 10-K · filed 2018-04-02 | |||
| 2017-09-30 | $19.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | $17.36M derived: sum of 2 quarters · filed 2018-11-13 | $15.13M 10-Q · filed 2018-11-13 | |||||
| 2017-06-30 | -$1.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | -$4.00M 10-Q · filed 2018-08-09 | ||||||
| 2017-03-31 | -$2.24M 10-Q · filed 2018-05-11 | |||||||
| 2016-12-31 | -$14.57M 10-K · filed 2018-04-02 | |||||||
| 2015-12-31 | -$10.16M 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |